Skip to content
2000
Volume 5, Issue 1
  • ISSN: 0250-6882
  • E-ISSN: 0250-6882
file format pdf download PDF
side by side viewer icon HTML

Abstract

Group 1 pulmonary artery hypertension (PAH) is a debilitating disease characterized by progressively increased pulmonary vascular resistance (PVR) and mean pulmonary arterial pressure (mPAP) due to obstructions in the pulmonary vasculature. Group 1 PAH is further subdivided into idiopathic PAH, PAH associated with congenital heart disease (PAH-CHD), PAH associated with connective tissue disease (CTD-PAH), portopulmonary hypertension (PoPH), and paediatric PAH, out of which the first 3 contribute to substantial disease burden. Evidence from registries suggests that survival rates are better in PAH-CHD, followed by idiopathic PAH and PAH-CTD. The cause of idiopathic PAH is not evident, but one-third of the patients belong to this group. CTD-PAH is the second most common cause of PAH, following idiopathic PAH. In all cases, lung transplantation is generally considered the last option when medical therapies are not working.

The current article discusses the various unmet needs in the UAE, including less effective monotherapy (exception considered in specific subsets of PAH), late referral to the PH expert center, no systemic follow-up (in patients with PAH-CHD), no routine assessment, and underutilization of screening and treatment algorithms.

This article highlights the current approach to classification, screening, diagnosis, and management of each type of Group 1 PAH. This also emphasizes the need for tailored therapy for each patient. Screening and treatment algorithms can help healthcare professionals in the early detection and effective management of PAH, respectively.

© 2024 The Author(s). Published by Bentham Science Publisher.
This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Loading

Article metrics loading...

/content/journals/nemj/10.2174/0102506882333527241023035848
2024-01-01
2025-07-22

  • From This Site

    /content/journals/nemj/10.2174/0102506882333527241023035848
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
The full text of this item is not currently available.

References

  1. LanN.S.H. MassamB.D. KulkarniS.S. LangC.C. Pulmonary arterial hypertension: Pathophysiology and treatment.Diseases2018623810.3390/diseases602003829772649
     [Google Scholar]
  2. SimonneauG. MontaniD. CelermajerD.S. DentonC.P. GatzoulisM.A. KrowkaM. WilliamsP.G. SouzaR. Haemodynamic definitions and updated clinical classification of pulmonary hypertension.Eur. Respir. J.2019531180191310.1183/13993003.01913‑201830545968
     [Google Scholar]
  3. SalehK. KhanN. DoughertyK. BodiG. MichalickovaM. MohammedS. KerenidiT. SadikZ. MallatJ. FarhaS. SabbourH. The first pulmonary hypertension registry in the united arab emirates (UAEPH): Clinical characteristics, hemodynamic parameters with focus on treatment and outcomes for patients with group 1-PH.J. Clin. Med.2023125199610.3390/jcm1205199636902782
     [Google Scholar]
  4. HumbertM. SitbonO. YaïciA. MontaniD. O’CallaghanD.S. JaïsX. ParentF. SavaleL. NataliD. GüntherS. ChaouatA. ChabotF. CordierJ-F. HabibG. GressinV. JingZ-C. SouzaR. SimonneauG. French Pulmonary Arterial Hypertension Network Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension.Eur. Respir. J.201036354955510.1183/09031936.0005701020562126
     [Google Scholar]
  5. McGoonM.D. MillerD.P. REVEAL: A contemporary US pulmonary arterial hypertension registry.Eur. Respir. Rev.20122112381810.1183/09059180.0000821122379169
     [Google Scholar]
  6. ChinK.M. SitbonO. DoelbergM. FeldmanJ. GibbsJ.S.R. GrünigE. HoeperM.M. MartinN. MathaiS.C. McLaughlinV.V. PerchenetL. PochD. SaggarR. SimonneauG. GalièN. Three- versus two-drug therapy for patients with newly diagnosed pulmonary arterial hypertension.J. Am. Coll. Cardiol.202178141393140310.1016/j.jacc.2021.07.05734593120
     [Google Scholar]
  7. HumbertM. McLaughlinV. GibbsJ.S.R. Gomberg-MaitlandM. HoeperM.M. PrestonI.R. SouzaR. WaxmanA. Escribano SubiasP. FeldmanJ. MeyerG. MontaniD. OlssonK.M. ManimaranS. BarnesJ. LindeP.G. de Oliveira PenaJ. BadeschD.B. PULSAR Trial Investigators Sotatercept for the treatment of pulmonary arterial hypertension.N. Engl. J. Med.2021384131204121510.1056/NEJMoa202427733789009
     [Google Scholar]
  8. WaxmanA. Restrepo-JaramilloR. ThenappanT. RavichandranA. EngelP. BajwaA. AllenR. FeldmanJ. ArgulaR. SmithP. RollinsK. DengC. PetersonL. BellH. TapsonV. NathanS.D. Inhaled treprostinil in pulmonary hypertension due to interstitial lung disease.N. Engl. J. Med.2021384432533410.1056/NEJMoa200847033440084
     [Google Scholar]
  9. GalièN. ChannickR.N. FrantzR.P. GrünigE. JingZ.C. MoiseevaO. PrestonI.R. PulidoT. SafdarZ. TamuraY. McLaughlinV.V. Risk stratification and medical therapy of pulmonary arterial hypertension.Eur. Respir. J.2019531180188910.1183/13993003.01889‑201830545971
     [Google Scholar]
  10. MaronB.A. AbmanS.H. ElliottC.G. FrantzR.P. HopperR.K. HornE.M. NicollsM.R. ShlobinO.A. ShahS.J. KovacsG. OlschewskiH. RosenzweigE.B. Pulmonary arterial hypertension: Diagnosis, treatment, and novel advances.Am. J. Respir. Crit. Care Med.2021203121472148710.1164/rccm.202012‑4317SO33861689
     [Google Scholar]
  11. GalièN. HumbertM. VachieryJ.L. GibbsS. LangI. TorbickiA. SimonneauG. PeacockA. Vonk NoordegraafA. BeghettiM. GhofraniA. Gomez SanchezM.A. HansmannG. KlepetkoW. LancellottiP. MatucciM. McDonaghT. PierardL.A. TrindadeP.T. ZompatoriM. HoeperM. ESC Scientific Document Group 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.Eur. Heart J.20163716711910.1093/eurheartj/ehv31726320113
     [Google Scholar]
  12. HumbertM. KovacsG. HoeperM.M. BadagliaccaR. BergerR.M.F. BridaM. CarlsenJ. CoatsA.J.S. Escribano-SubiasP. FerrariP. FerreiraD.S. GhofraniH.A. GiannakoulasG. KielyD.G. MayerE. MeszarosG. NagavciB. OlssonK.M. Pepke-ZabaJ. QuintJ.K. RådegranG. SimonneauG. SitbonO. ToniaT. ToshnerM. VachieryJ.L. Vonk NoordegraafA. DelcroixM. RosenkranzS. ESC/ERS Scientific Document Group 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.Eur. Respir. J.2023611220087910.1183/13993003.00879‑202236028254
     [Google Scholar]
  13. BarstR.J. RubinL.J. LongW.A. McGoonM.D. RichS. BadeschD.B. GrovesB.M. TapsonV.F. BourgeR.C. BrundageB.H. KoernerS.K. LanglebenD. KellerC.A. MuraliS. UretskyB.F. ClaytonL.M. JöbsisM.M. BlackburnS.D.Jr ShortinoD. CrowJ.W. Primary Pulmonary Hypertension Study Group A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension.N. Engl. J. Med.1996334529630110.1056/NEJM1996020133405048532025
     [Google Scholar]
  14. SitbonO. JaïsX. SavaleL. CottinV. BergotE. MacariE.A. BouvaistH. DauphinC. PicardF. BulifonS. MontaniD. HumbertM. SimonneauG. Upfront triple combination therapy in pulmonary arterial hypertension: A pilot study.Eur. Respir. J.20144361691169710.1183/09031936.0011631324627535
     [Google Scholar]
  15. SabbourH. Challenges and evolution of prostanoid therapies in the Middle East insights from UAE PH database.2019 Pulmonary Hypertension Association Pulmonary Hypertension Professional Network SymposiumWashington, 2019.
     [Google Scholar]
  16. SitbonO. ChannickR. ChinK.M. FreyA. GaineS. GalièN. GhofraniH.A. HoeperM.M. LangI.M. PreissR. RubinL.J. Di ScalaL. TapsonV. AdzerikhoI. LiuJ. MoiseevaO. ZengX. SimonneauG. McLaughlinV.V. GRIPHON Investigators Selexipag for the treatment of pulmonary arterial hypertension.N. Engl. J. Med.2015373262522253310.1056/NEJMoa150318426699168
     [Google Scholar]
  17. JansaP. PulidoT. Macitentan in pulmonary arterial hypertension: A focus on combination therapy in the seraphin trial.Am. J. Cardiovasc. Drugs201818111110.1007/s40256‑017‑0260‑129280064
     [Google Scholar]
  18. SitbonO. BoschJ. CottreelE. CsonkaD. de GrooteP. HoeperM.M. KimN.H. MartinN. SavaleL. KrowkaM. Macitentan for the treatment of portopulmonary hypertension (PORTICO): A multicentre, randomised, double-blind, placebo-controlled, phase 4 trial.Lancet Respir. Med.20197759460410.1016/S2213‑2600(19)30091‑831178422
     [Google Scholar]
  19. USFDA WINREVAIR™ (sotatercept-csrk) for injection, for subcutaneous use.2024Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761363s000lbl.pdf2024
  20. HoeperM.M. BadeschD.B. GhofraniH.A. GibbsJ.S.R. Gomberg-MaitlandM. McLaughlinV.V. PrestonI.R. SouzaR. WaxmanA.B. GrünigE. KopećG. MeyerG. OlssonK.M. RosenkranzS. XuY. MillerB. FowlerM. ButlerJ. KoglinJ. de Oliveira PenaJ. HumbertM. STELLAR Trial Investigators Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension.N. Engl. J. Med.2023388161478149010.1056/NEJMoa221355836877098
     [Google Scholar]
  21. PascallE. TullohR.M.R. Pulmonary hypertension in congenital heart disease.Future Cardiol.201814434335310.2217/fca‑2017‑006529792339
     [Google Scholar]
  22. EngelfrietP.M. DuffelsM.G.J. MöllerT. BoersmaE. TijssenJ.G.P. ThaulowE. GatzoulisM.A. MulderB.J.M. Pulmonary arterial hypertension in adults born with a heart septal defect: The Euro Heart Survey on adult congenital heart disease.Heart200793668268710.1136/hrt.2006.09884817164490
     [Google Scholar]
  23. DuffelsM.G.J. EngelfrietP.M. BergerR.M.F. van LoonR.L.E. HoendermisE. VriendJ.W.J. van der VeldeE.T. BresserP. MulderB.J.M. Pulmonary arterial hypertension in congenital heart disease: An epidemiologic perspective from a Dutch registry.Int. J. Cardiol.2007120219820410.1016/j.ijcard.2006.09.01717182132
     [Google Scholar]
  24. CondliffeR. Pulmonary arterial hypertension associated with congenital heart disease: Classification and pathophysiology.J Congenit Heart Dis20204Suppl 11610.1186/s40949‑020‑00040‑0
     [Google Scholar]
  25. FrostA. BadeschD. GibbsJ.S.R. GopalanD. KhannaD. ManesA. OudizR. SatohT. TorresF. TorbickiA. Diagnosis of pulmonary hypertension.Eur. Respir. J.2019531180190410.1183/13993003.01904‑201830545972
     [Google Scholar]
  26. LopesA. AlnajashiK. Saudi guidelines on the diagnosis and treatment of pulmonary hypertension: Pulmonary arterial hypertension associated with congenital heart disease.Ann. Thorac. Med.201495Suppl. 12110.4103/1817‑1737.13401525076993
     [Google Scholar]
  27. ThomasC. GlinskiiV. de Jesus PerezV. SahayS. Portopulmonary hypertension: From bench to bedside.Front. Med.2020756941310.3389/fmed.2020.56941333224960
     [Google Scholar]
  28. Le PavecJ. SouzaR. HerveP. LebrecD. SavaleL. TcherakianC. JaïsX. YaïciA. HumbertM. SimonneauG. SitbonO. Portopulmonary Hypertension.Am. J. Respir. Crit. Care Med.2008178663764310.1164/rccm.200804‑613OC18617641
     [Google Scholar]
  29. KrowkaM.J. MillerD.P. BarstR.J. TaichmanD. DweikR.A. BadeschD.B. McGoonM.D. Portopulmonary Hypertension.Chest2012141490691510.1378/chest.11‑016021778257
     [Google Scholar]
  30. SithamparanathanS. NairA. ThirugnanasothyL. CoghlanJ.G. CondliffeR. DimopoulosK. ElliotC.A. FisherA.J. GaineS. GibbsJ.S.R. GatzoulisM.A. E HandlerC. HowardL.S. JohnsonM. KielyD.G. LordanJ.L. PeacockA.J. Pepke-ZabaJ. SchreiberB.E. ShearesK.K.K. WortS.J. CorrisP.A. National Pulmonary Hypertension Service Research Collaboration of the United Kingdom and Ireland Survival in portopulmonary hypertension: Outcomes of the united kingdom national pulmonary arterial hypertension registry.J. Heart Lung Transplant.201736777077910.1016/j.healun.2016.12.01428190786
     [Google Scholar]
  31. BozbasS. EyubogluF. Evaluation of liver transplant candidates: A pulmonary perspective.Ann. Thorac. Med.20116310911410.4103/1817‑1737.8243621760840
     [Google Scholar]
  32. Cartin-CebaR. KrowkaM.J. Portopulmonary Hypertension.Clin. Liver Dis.201418242143810.1016/j.cld.2014.01.00424679504
     [Google Scholar]
  33. KawutS.M. KrowkaM.J. TrotterJ.F. RobertsK.E. BenzaR.L. BadeschD.B. TaichmanD.B. HornE.M. ZacksS. KaplowitzN. BrownR.S.Jr FallonM.B. Pulmonary Vascular Complications of Liver Disease Study Group Clinical risk factors for portopulmonary hypertension.Hepatology200848119620310.1002/hep.2227518537192
     [Google Scholar]
  34. CosardereliogluC. CosarA.M. GurakarM. PustavoitauA. RussellS.D. DagherN.N. GurakarA. Portopulmonary hypertension and liver transplant: Recent review of the literature.Exp. Clin. Transplant.201614211312027015528
     [Google Scholar]
  35. SaleemiS. IdreesM. Saudi guidelines on the diagnosis and treatment of pulmonary hypertension: Portopulmonary hypertension.Ann. Thorac. Med.201495Suppl. 14210.4103/1817‑1737.13402125076996
     [Google Scholar]
  36. HoeperM.M. KrowkaM.J. StrassburgC.P. Portopulmonary hypertension and hepatopulmonary syndrome.Lancet200436394191461146810.1016/S0140‑6736(04)16107‑215121411
     [Google Scholar]
  37. Rodríguez-RoisinR. KrowkaM.J. HervéP. FallonM.B. ERS Task Force Pulmonary-Hepatic Vascular Disorders (PHD) Scientific Committee Pulmonary–Hepatic vascular Disorders (PHD).Eur. Respir. J.200424586188010.1183/09031936.04.0001090415516683
     [Google Scholar]
  38. KrowkaM.J. FrantzR.P. McGoonM.D. SeversonC. PlevakD.J. WiesnerR.H. Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): A study of 15 patients with moderate to severe portopulmonary hypertension.Hepatology199930364164810.1002/hep.51030030710462369
     [Google Scholar]
  39. FixO.K. BassN.M. De MarcoT. MerrimanR.B. Long-term follow-up of portopulmonary hypertension: Effect of treatment with epoprostenol.Liver Transpl.200713687588510.1002/lt.2117417539008
     [Google Scholar]
  40. ReichenbergerF. VoswinckelR. StevelingE. EnkeB. KreckelA. OlschewskiH. GrimmingerF. SeegerW. GhofraniH.A. Sildenafil treatment for portopulmonary hypertension.Eur. Respir. J.200628356356710.1183/09031936.06.0003020616807265
     [Google Scholar]
  41. GhofraniH.A. GalièN. GrimmingerF. GrünigE. HumbertM. JingZ.C. KeoghA.M. LanglebenD. KilamaM.O. FritschA. NeuserD. RubinL.J. PATENT-1 Study Group Riociguat for the treatment of pulmonary arterial hypertension.N. Engl. J. Med.2013369433034010.1056/NEJMoa120965523883378
     [Google Scholar]
  42. ADEMPAS ADEMPAS (riociguat) tablets, for oral use.2013Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/204819s006lbl.pdf
  43. GrannasG. NeippM. HoeperM.M. GottliebJ. LückR. BeckerT. SimonA. StrassburgC.P. MannsM.P. WelteT. HaverichA. KlempnauerJ. NashanB. StrueberM. Indications for and outcomes after combined lung and liver transplantation: A single-center experience on 13 consecutive cases.Transplantation200885452453110.1097/TP.0b013e3181636f3f18347530
     [Google Scholar]
  44. FrankB. IvyD. Diagnosis, evaluation and treatment of pulmonary arterial hypertension in children.Children2018544410.3390/children504004429570688
     [Google Scholar]
  45. RosenzweigE.B. AbmanS.H. AdatiaI. BeghettiM. BonnetD. HaworthS. IvyD.D. BergerR.M.F. Paediatric pulmonary arterial hypertension: Updates on definition, classification, diagnostics and management.Eur. Respir. J.2019531180191610.1183/13993003.01916‑201830545978
     [Google Scholar]
/content/journals/nemj/10.2174/0102506882333527241023035848
Loading
Diagnosis and Management of Group 1 Pulmonary Arterial Hypertension in the UAE
NEW Emirates Medical J 5, e02506882333527 (2024); https://doi.org/10.2174/0102506882333527241023035848
/content/journals/nemj/10.2174/0102506882333527241023035848
/content/journals/nemj/10.2174/0102506882333527241023035848
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): Calcium-channel blockers; Congenital heart disease; Eisenmenger syndrome; Endothelin receptor antagonists; Liver function test; Randomized controlled trials

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test